M&A Deal Summary |
|
---|---|
Date | 2021-10-01 |
Target | QInstruments |
Sector | Medical Products |
Buyer(s) | BICO |
Deal Type | Add-on Acquisition |
Deal Value | 61M EUR |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2016 |
Sector | Life Science |
Employees | 832 |
Revenue | 2.3B SEK (2023) |
BICO is a bio convergence company that combines different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology. With a focus on the application areas of bioprinting, multi-omics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO was founded in 2016 and is based in Gothenburg, Sweden.
DEAL STATS | # |
---|---|
Overall | 3 of 3 |
Sector (Medical Products) | 1 of 1 |
Type (Add-on Acquisition) | 3 of 3 |
Country (Germany) | 1 of 1 |
Year (2021) | 3 of 3 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-09-15 |
Hurel
North Brunswick Township, New Jersey, United States Hurel uses cell biology and microfluidics in a “chip” to help drug companies predict pre-clinically the drug candidates with the best chances of winning FDA approval. Hurel was founded in 2005 and is based in North Brunswick Township, New jersey. |
Buy | - |